MOTS-c and tesamorelin are searched together because both are discussed in relation to metabolism and body fat. MOTS-c is a peptide encoded in mitochondrial DNA, studied as a metabolic regulator. Tesamorelin is an analog of growth hormone-releasing hormone (GHRH), FDA-approved as Egrifta for HIV-associated lipodystrophy.
At a glance
| MOTS-c | Tesamorelin | |
|---|---|---|
| What it is | Peptide encoded in mitochondrial DNA, studied as a metabolic regulator and sometimes called an exercise mimetic | Stabilized GHRH analog, FDA-approved as Egrifta for visceral fat in HIV-associated lipodystrophy |
| How it's thought to work | Studied for moving to the cell nucleus under metabolic stress and activating AMPK signaling, affecting glucose and fat metabolism | Stimulates pulsatile GH release, raising IGF-1 and preferentially mobilizing visceral abdominal fat |
| Regulatory status | Not FDA-approved for any human use | FDA-approved for HIV-associated lipodystrophy specifically; other uses are off-label |
| Strength of evidence | Insulin-sensitivity and exercise findings come from animal studies; human research is at an early stage | Multiple human clinical trials support visceral fat reduction; basis for FDA approval |
| Reported side effects | Injection site reactions; long-term human data is limited | Injection site reactions, joint pain, fluid retention, tingling, elevated blood sugar |
| Common vial sizes | 5mg, 10mg | 2mg, 5mg, 10mg |
| Mixing math example | 10 mg + 2 mL BAC water = 5,000 mcg/mL, 50 mcg per unit | 5 mg + 2 mL BAC water = 2,500 mcg/mL, 25 mcg per unit |
Key differences
MOTS-c is studied for activating AMPK signaling inside cells under metabolic stress, affecting glucose use and fat metabolism. Tesamorelin acts on the pituitary to stimulate pulsatile growth hormone release, raising IGF-1, and research describes it as preferentially mobilizing visceral abdominal fat.
Tesamorelin is FDA-approved for HIV-associated lipodystrophy, and other uses are off-label. MOTS-c is not FDA-approved for any human use.
MOTS-c's reported side effects are injection site reactions, and long-term human data is limited. Tesamorelin's reported side effects include injection site reactions, joint pain, fluid retention, tingling and elevated blood sugar.
What the research covers
Tesamorelin has multiple human clinical trials of visceral fat reduction, the basis of its FDA approval. MOTS-c's findings on insulin sensitivity and exercise capacity come from animal studies, and human research is at an early stage.
Sources
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Lee C et al. Cell Metabolism, 2015. Preclinical
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Reynolds JC et al. Nature Communications, 2021. Human trial
- Metabolic effects of a growth hormone-releasing factor in patients with HIV. Falutz J et al. N Engl J Med, 2007. Human trial
- EGRIFTA (tesamorelin for injection), for subcutaneous use - Prescribing Information. U.S. Food and Drug Administration, 2019. Fda label
Frequently asked questions
What is the difference between MOTS-c and tesamorelin?
MOTS-c is a mitochondrial-encoded peptide studied for AMPK signaling and metabolism. Tesamorelin is a GHRH analog that raises growth hormone release and is FDA-approved as Egrifta.
Is MOTS-c or tesamorelin FDA-approved?
Tesamorelin is FDA-approved for HIV-associated lipodystrophy only. MOTS-c is not FDA-approved for any human use.
Do MOTS-c and tesamorelin work the same way?
No. MOTS-c acts inside cells through AMPK signaling, while tesamorelin acts on the pituitary to raise growth hormone release.
Which has more human research, MOTS-c or tesamorelin?
Tesamorelin has more, with multiple human trials supporting its approval. MOTS-c human research is at an early stage.
Both entries, plus the calculator
The PeptidesAI app covers MOTS-c, Tesamorelin and 68 other compounds, with a reconstitution calculator, a dose log and reminders. Free to download on iPhone.
Download on the App Store